Teva Pharmaceutical Industries Ltd. ADR logo

Teva Pharmaceutical Industries Ltd. ADR (0LER)

Market Closed
17 Apr, 15:30
$
13. 60
-0.1
-0.73%
$
- Market Cap
- P/E Ratio
0.34% Div Yield
3,407 Volume
- Eps
$ 13.7
Previous Close
Day Range
13.41 13.71
Year Range
12.49 22.8
Earnings results expected in 15 days

Summary

0LER closed Thursday lower at $13.6, a decrease of 0.73% from Wednesday's close, completing a monthly decrease of -8.72% or $1.3. Over the past 12 months, 0LER stock lost -39.15%.
0LER pays dividends to its shareholders, with the most recent payment made on Dec 12, 2017. The next estimated payment will be in 12 Mar 2018 on Mar 12, 2018 for a total of $0.085.
The last earnings report, released on Jan 29, 2025, exceeded the consensus estimates by 0.01%. On average, the company has surpassed earnings expectations by 0.04%, based on the last three reports. The next scheduled earnings report is due on May 06, 2025.
The stock of the company had never split.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track 0LER and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

0LER Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.

Teva Pharmaceutical Industries Ltd. ADR Dividends

Teva Pharmaceutical Industries Ltd logo
TEVA 27 Feb 2018
Estimated
Quarterly
$0.09 Per Share
Teva Pharmaceutical Industries Ltd logo
TEVA 27 Nov 2017
Paid
Quarterly
$0.09 Per Share
Teva Pharmaceutical Industries Ltd logo
TEVA 25 Aug 2017
Paid
Quarterly
$0.09 Per Share
Teva Pharmaceutical Industries Ltd logo
TEVA 1 Jun 2017
Paid
Quarterly
$0.34 Per Share
Teva Pharmaceutical Industries Ltd logo
TEVA 28 Feb 2017
Paid
Quarterly
$0.34 Per Share
Teva Pharmaceutical Industries Ltd logo
TEVA 1 Dec 2016
Paid
Quarterly
$0.34 Per Share

Teva Pharmaceutical Industries Ltd. ADR Earnings

6 May 2025 (15 Days) Date
-
Cons. EPS
-
EPS
29 Jan 2025 Date
0.7
Cons. EPS
0.71
EPS
6 Nov 2024 Date
0.65
Cons. EPS
0.69
EPS
31 Jul 2024 Date
0.55
Cons. EPS
0.61
EPS
8 May 2024 Date
0.51
Cons. EPS
0.48
EPS
Teva Pharmaceutical Industries Ltd logo
TEVA 27 Feb 2018
Estimated
Quarterly
$0.09 Per Share
Teva Pharmaceutical Industries Ltd logo
TEVA 27 Nov 2017
Paid
Quarterly
$0.09 Per Share
Teva Pharmaceutical Industries Ltd logo
TEVA 25 Aug 2017
Paid
Quarterly
$0.09 Per Share
Teva Pharmaceutical Industries Ltd logo
TEVA 1 Jun 2017
Paid
Quarterly
$0.34 Per Share
Teva Pharmaceutical Industries Ltd logo
TEVA 28 Feb 2017
Paid
Quarterly
$0.34 Per Share
Teva Pharmaceutical Industries Ltd logo
TEVA 1 Dec 2016
Paid
Quarterly
$0.34 Per Share
6 May 2025 (15 Days) Date
-
Cons. EPS
-
EPS
29 Jan 2025 Date
0.7
Cons. EPS
0.71
EPS
6 Nov 2024 Date
0.65
Cons. EPS
0.69
EPS
31 Jul 2024 Date
0.55
Cons. EPS
0.61
EPS
8 May 2024 Date
0.51
Cons. EPS
0.48
EPS

Teva Pharmaceutical Industries Ltd. ADR (0LER) FAQ

What is the stock price today?

The current price is $13.60.

On which exchange is it traded?

Teva Pharmaceutical Industries Ltd. ADR is listed on NYSE.

What is its stock symbol?

The ticker symbol is 0LER.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on May 06, 2025.

Has Teva Pharmaceutical Industries Ltd. ADR ever had a stock split?

No, there has never been a stock split.

Teva Pharmaceutical Industries Ltd. ADR Profile

Drug Manufacturers—Specialty & Generic Industry
Healthcare Sector
Mr. Richard D. Francis CEO
LSE Exchange
US8816242098 ISIN
Israel Country
35,001 Employees
12 Dec 2017 Last Dividend
1 Jul 2004 Last Split
- IPO Date

Overview

Teva Pharmaceutical Industries Limited is a prominent global company with a focus on developing, manufacturing, marketing, and distributing a wide range of pharmaceutical products. Its operations span across North America, Europe, Israel, and other international markets. Teva's portfolio includes generic medicines, specialty medicines, and biopharmaceutical products, catering to various dosage forms and therapeutic areas. With a history dating back to 1901, the company has established itself as a leader in the pharmaceutical industry, headquartered in Tel Aviv, Israel. Teva is known for its contribution to central nervous system (CNS), respiratory, and oncology therapeutic areas, providing active pharmaceutical ingredients and contract manufacturing services, alongside operating an out-licensing platform for other pharmaceutical companies. Teva's commitment to healthcare and therapeutic advancements is evident through its collaboration agreements with MedinCell, Sanofi, Alvotech, and Biolojic Design Ltd., as well as a license agreement with MODAG GmbH.

Products and Services

BENDEKA and TREANDA injections: Used for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma, these injections underscore Teva's focus on oncology.

GRANIX, TRISENOX, LONQUEX, and TEVAGRASTIM/RATIOGRASTIM: These products exemplify Teva's commitment to providing supportive care in oncology, including treatments for neutropenia and arsenic trioxide for leukemia.

COPAXONE: This flagship product for the treatment of relapsing forms of multiple sclerosis highlights Teva's innovation in CNS therapies.

AJOVY: A treatment for the preventive care of migraine in adults, AJOVY is part of Teva's specialty medicine range aimed at improving quality of life for migraine sufferers.

AUSTEDO: Focused on neurodegenerative and movement disorders, AUSTEDO is used for treating conditions associated with Huntington's disease and tardive dyskinesia.

UZEDY: This antipsychotic is used for the treatment of schizophrenia, reflecting Teva's ongoing development in CNS health.

Respiratory Products: Teva offers a suite of respiratory products like ProAir RespiClick inhalation powder, QVAR for asthma, BRALTUS, CINQAIR/CINQAERO injection, DuoResp Spiromax, and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder, addressing a broad spectrum of respiratory conditions.

OTC Products: Teva's over-the-counter (OTC) offerings under brands such as SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA, cater to a variety of everyday health needs, from skincare to cold and flu relief.

In addition to its broad spectrum of pharmaceutical products, Teva Pharmaceutical Industries Limited also provides active pharmaceutical ingredients and contract manufacturing services, demonstrating its versatility and comprehensive approach to healthcare solutions.

Contact Information

Address: 124 Dvora HaNevi’a Street
Phone: 972 3 914 8213